Download PDF
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2022; 26(03): e293-e295
DOI: 10.1055/s-0042-1750202
Letter to the Editor

Oral Antiseptic Spray Containing Phthalocyanine Solution Reduced Saliva SARS-CoV-2 Viral Load: Case Series

Bernardo da Fonseca Orcina 
1   Department of Surgery, Stomatology, Pathology, and Radiology, Faculdade de Odontologia de Bauru da Universidade deSão Paulo, São Paulo, SP, Brazil
,
Emilene Cristine Izu Nakamura Pietro 
2   Control Infection Comission, Hospital Estadual de Bauru, Bauru, SP, Brazil
,
Juliana Pescinelli Garcia Kuroda 
2   Control Infection Comission, Hospital Estadual de Bauru, Bauru, SP, Brazil
,
Lucas Marques da Costa Alves 
2   Control Infection Comission, Hospital Estadual de Bauru, Bauru, SP, Brazil
,
Mariana Schutzer Ragghianti Zangrando 
3   Department of Oral Rehabilitation and Periodontology, Faculdade de Odontologia de Bauru da Universidade de São Paulo, São Paulo, SP, Brazil
,
Rodrigo Cardoso de Oliveira 
4   Department of Oral Biology, Faculdade de Odontologia de Bauru da Universidade de São Paulo, Bauru, SP, Brazil
,
Andréa Name Colado Simão 
5   Department of Immunology, Universidade Estadual de Londrina, Londrina, PR, Brazil
,
Fabiano Vieira Vilhena 
6   TRIALS Oral Health and Technologies
,
Paulo Sérgio da Silva Santos 
1   Department of Surgery, Stomatology, Pathology, and Radiology, Faculdade de Odontologia de Bauru da Universidade deSão Paulo, São Paulo, SP, Brazil
› Author Affiliations Funding Dr. F. V. Vilhena reports grants from TRIALS Inc, during the conduct of the study; in addition, Dr. F. V. Vilhena has a patent.
› Further Information
   Permissions and Reprints

Introduction

Since the 2019 global dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), scientific advancements have enabled researchers to develop different types of vaccines and other forms of prevention and treatment against coronavirus disease 2019 (COVID-19).[1] The oral cavity is related to the development of COVID-19 as it allows the virus direct access into the body.[2] [3] [4] According to the literature, clinical evidence has demonstrated that antiviral oral solutions can inactivate SARS-CoV-2 and reduce clinical symptoms and severity of COVID-19.[2] [5] [6] [7] [8] Based on previous in vitro studies employing antiviral phthalocyanine derivative (APD) solutions,[6] [9] this case series evaluated the action of an APD oral spray for viral load reduction in COVID-19 hospitalized patients.



Publication History

Received: 22 August 2021

Accepted: 02 May 2022

Article published online:
14 July 2022

© 2022. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Bakadia BM, He F, Souho T. et al. Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomed Pharmacother 2021; 133: 111008 DOI: 10.1016/j.biopha.2020.111008.
    CrossrefPubMedGoogle Scholar
  • 2 Huang N, Pérez P, Kato T. et al; NIH COVID-19 Autopsy Consortium, HCA Oral and Craniofacial Biological Network. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med 2021; 27 (05) 892-903 DOI: 10.1038/s41591-021-01296-8.
    CrossrefPubMedGoogle Scholar
  • 3 Fernandes Matuck B, Dolhnikoff M, Maia GVA. et al. Periodontal tissues are targets for Sars-Cov-2: a post-mortem study. J Oral Microbiol 2020; 13 (01) 1848135 DOI: 10.1080/20002297.2020.1848135.
    CrossrefPubMedGoogle Scholar
  • 4 Matuck BF, Dolhnikoff M, Duarte-Neto AN. et al. Salivary glands are a target for SARS-CoV-2: a source for saliva contamination. J Pathol 2021; 254 (03) 239-243 DOI: 10.1002/path.5679.
    CrossrefPubMedGoogle Scholar
  • 5 Mateos-Moreno MV, Mira A, Ausina-Márquez V, Ferrer MD. Oral antiseptics against coronavirus: in-vitro and clinical evidence. J Hosp Infect 2021; 113: 30-43 DOI: 10.1016/j.jhin.2021.04.004.
    CrossrefPubMedGoogle Scholar
  • 6 Santos PSS, Fonseca OrcinaB, Machado RRG. et al. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: Randomised trial. Sci Rep 2021 Oct 7. PMID: 34620904; PMCID: PMC8497631.11(01):19937. Doi: 10.1038/s41598-021-99013
    Google Scholar
  • 7 da Fonseca Orcina B, Vilhena FV, Cardoso de Oliveira R. et al. A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series. Clin Cosmet Investig Dent 2021; 13: 47-50 DOI: 10.2147/CCIDE.S295423.
    CrossrefPubMedGoogle Scholar
  • 8 Carrouel F, Valette M, Gadea E. et al. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect 2021; 27 (10) 1494-1501
    CrossrefPubMedGoogle Scholar
  • 9 Santos C, da Fonseca Orcina B, Brito Reia VC. et al. Virucidal activity of the antiseptic mouthwash and dental gel containing anionic phthalocyanine derivative: in vitro study. Clin Cosmet Investig Dent 2021; 13: 269-274 DOI: 10.2147/CCIDE.S315419.
    CrossrefPubMedGoogle Scholar
  • 10 Huang YH, Huang JT. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients. J Med Virol 2021; 93 (07) 4370-4373 DOI: 10.1002/jmv.26954.
    CrossrefPubMedGoogle Scholar